PRTODAY / NewswireToday Free press release distribution service network

More news: Research
Written by / Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

ErbB2 and p53 – Important Antibodies for Cancer Research - The overexpression of the c-erbB-2 (HER-2/neu) gene product, a 185 kDa transmembrane receptor protein, is associated with cell transformation and tumorigenesis.
ErbB2 and p53 – Important Antibodies for Cancer Research

 

NewswireToday - /newswire/ - San Jose, CA, United States, 2006/11/06 - The overexpression of the c-erbB-2 (HER-2/neu) gene product, a 185 kDa transmembrane receptor protein, is associated with cell transformation and tumorigenesis..

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Research Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

It shares homology with the epidermal growth factor receptor and intrinsic tyrosine kinase activity, HER-2/neu gene is amplified and overexpressed in 25-30% of human breast and ovarian cancers. Overexpression of the protein, as determined by immunohistochemistry, is associated with poor prognosis (1,2).

One of the most important mammalian cell cycle checkpoint proteins is the tumor suppressor protein, p53. In normal, undamaged cells, p53 is rapidly degraded. However, when cells are treated with DNA damage-inducing agents, there is a transient accumulation of p53 protein and it is activated as a transcription factor. In several types of human cancers, p53 is mutated (3,4). Human p53 protein has been shown to be phosphorylated at several N-terminal and C-terminal sites that affect site-specific DNA binding and interaction with other cellular and viral proteins in vitro (5-10). Phosphorylation at serines 6, 9, 15, 20, 33, 37 occur after cells are exposed either to ionizing radiation or to UV light (11,12). Serines 6 and 15 were demonstrated to be one of the strongest and earliest phosphorylated sites in response to DNA damage-induced posttranslational modifications (13, 14).

With a focus on providing targeted solutions for cancer research, AnaSpec, a leading provider of integrated proteomics solutions, offers a highly specific selection of c-erbB-2 (HER-2/ neu) and p53 polyclonal antibodies. AnaSpec’s collection of p53 antibody products includes both phosphospecific and non-phosphospecific solutions.

• Anti-C-erbB-2

• Anti-P53 (pSer6), phospho-specific

• Anti-P53 (Paired6), non-phospho-specific

• Anti-P53 (pSer9), phospho-specific

• Anti-P53 (Paired9), non-phospho-specific

• Anti-P53 (pSer15), phospho-specific

• Anti-P53 (Paired15), non-phospho-specific

References:

1. Hudson, LG. et al. J. Biol. Chem. 265, 2389 (1990).
2. Reese, DM and DJ. Slamon. Stem Cells 15, 1 (1997).
3. Brown, JM et al (1999) Cancer Res. 59:1391-1399
4. Albrechtsen, N et al (1999) Oncogene 18:7706-7717
5. Wang, L. et al (2001) J. Biol Chem. 276, 43604 (2001).
6. Xirodimas, D et al (2001) Oncogene 20 (36):4972-83
7. Backlund, MG et al (2001) Cancer Res. 61(17): 6577-82
8. Sakaguchi, K et al (2000) J. Biol. Chem. 275:9278-83
9. Banin, S et al (1998) Science 281: 1674-1677
10. Canman, CE et al (1998) Science 281: 1677-1679
11. Burns, TF et al J. cell Physiol. 181: 231-239
12. Oren, M et al (1999) J. Biol. Chem 274:36031-36034
13. Lakin, ND et al (1999) Oncogene 18: 7644-7655
14. Higashimoto, Y et al (2000) J Biol Chem. 275:23199-23203

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Research Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: AnaSpec, Inc.

 
 

Availability: All Metropolitan Area

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Research articles,
CATCH Visitors via Your Competitors Announcements!


ErbB2 and p53 – Important Antibodies for Cancer Research

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Debra Thai 
408-452-5055 marketing[.]anaspec.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Research via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From AnaSpec, Inc. / Company Profile


Read Research Most Recent Related Newswires:

DSM Announces Partnership with Cerapedics to Develop and Manufacture Next Generation of Peptide Enhanced Bone Graft
DSM Announces Somos® Distribution Agreement with RP America
Thales Selects Canada as New Global Hub to Boost Artificial Intelligence Expertise
DSM High-temperature Plastics Successfully Replace Metal in Charge Air Cooler End Cap Application
DSM Developing Novel Materials Solution for High-pressure Composite Tanks for Hydrogen Storage
DSM Brings Digestive Comfort to Gluten Sensitive Adults with Launch of Unique Enzyme
DSM Announces Exclusive Partnership with Nanjing Cosmos Chemical Co., Ltd and Plans to Continue Expansion in UV Filters
DSM Launches New Enzyme Solutions At IFT17 to Improve Softness and Moistness of Gluten-free Bread
DSM and Evonik Select Nebraska for Production of Breakthrough Omega-3
Phasor to Develop Next Generation Electronically Steerable Antenna Featuring DSM Dyneema’s Advanced Radome Solution
DSM’s Delvotest® T Antibiotic Residue Test for Milk Validated by Finnish Food Safety Authority
Royal DSM to Make Equity Investment in Amyris with the Purpose of Establishing A Long-term Relationship
DSM Unveils New Beauty Active At NYSCC Suppliers’ Day
Iridea Bio - A New Sustainable Paint Made with DSM’s Decovery® Plant-based Resin
DSM to Showcase A Wide Range of Innovative Composite Solutions

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)